Image-guided stereotactic ablative radiotherapy for the liver: A safe and effective treatment

Abstract

SABR is a safe and efficient treatment for selected inoperable patients or irresectable tumors of the liver. Future studies should combine SABR with systemic treatment acting in synergy with radiation, such as immunological interventions or hypoxic cell radiosensitizers to prevent distant relapse.

SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques

“…Most of the published studies reported treatments performed on linear accelerator (see Table 1). [13][14][15][16][17][18][19][20][21][22][23][24][25] Some other reported treatments on Cyberknife ® 26-29 or other machines dedicated for SBRT treatments. 30,31 There is a large heterogeneity in dose prescription and fractionation used.…”

Robotic intrafractional US guidance for liver SABR: System design, beam avoidance, and clinical imaging

“…Image-guided liver stereotactic ablative body radiotherapy (SABR) has emerged as a safe and effective noninvasive treatment option for patients with inoperable liver tumors. 1 Realizing the full potential of liver SABR by minimizing normal tissue irradiation and maximizing tumor dose is contingent on having the clinical capabilities to adequately manage respiratory-induced quasiperiodic liver motion. 2,3 Abdominal compression techniques have been investigated to reduce respiratory liver motion, but in the majority of patients (60%) the magnitude of motion reduction is clinically not significant (<3 mm).…”

What is the degree of innovation routinely implemented in Dutch radiotherapy centres? A multicentre cross-sectional study

“…5–7 Successful examples include stereotactic RT of intracranial and extracranial primary tumours and metastases and the incorporation of molecular imaging in treatment planning. 4,8,9 Organizational innovations, such as adopting the lean philosophy and introducing lean tools, can also help to decrease waiting times and increase safety and cost-effectiveness. 10–12 Both lower doses to normal tissues and shorter waiting times or fewer interruptions of the treatment are clearly desirable outcomes.…”